Weight Loss with FT218, a Once-Nightly Sodium Oxybate Formulation (ON-SXB), for the Treatment of Narcolepsy: Post Hoc Analysis from REST-ON

被引：0
|
作者：
Morse, Anne Marie [1 ]
Roy, Asim [2 ]
Dubow, Jordan [3 ]
Seiden, David [3 ]
Bogan, Richard [4 ,5 ]
机构：
[1] Janet Weis Childrens Hosp, Geisinger Med Ctr, Geisinger Commonwealth Sch Med, Danville, PA USA
[2] Ohio Sleep Med Inst, Dublin, OH USA
[3] Avadel Pharmaceut, Chesterfield, MO USA
[4] Univ South Carolina, Sch Med, Charleston, SC USA
[5] Med Univ SC, Charleston, SC USA
来源：
ANNALS OF NEUROLOGY | 2021年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
286
引用
收藏
页码：S242 / S242
页数：1
相关论文
共 50 条
  • [21] PIVOTAL PHASE 3 STUDY OF FT218, A ONCE-NIGHTLY SODIUM OXYBATE FORMULATION, IN PATIENTS WITH NARCOLEPSY: REST-ON PRIMARY RESULTS
    Kushida, Clete
    Shapiro, Colin
    Roth, Thomas
    Thorpy, Michael
    Rosenberg, Russell
    Corser, Bruce
    Ajayi, Akinyemi
    Dubow, Jordan
    Seiden, David
    Dauvilliers, Yves
    SLEEP, 2021, 44 : A193 - A193
  • [22] Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial
    Dauvilliers, Yves
    Roth, Thomas
    Bogan, Richard
    Thorpy, Michael J.
    Morse, Anne Marie
    Roy, Asim
    Dubow, Jordan
    Gudeman, Jennifer
    SLEEP, 2023, 46 (11)
  • [23] CATAPLEXY RESPONSE WITH FT218 (ONCE-NIGHTLY SODIUM OXYBATE): POST HOC RESPONDER ANALYSIS FROM THE PHASE 3 REST-ON CLINICAL TRIAL
    Thorpy, Michael
    Kushida, Clete
    Ajayi, Akinyemi
    Dubow, Jordan
    Gudeman, Jennifer
    SLEEP, 2023, 46
  • [24] CATAPLEXY RESPONSE WITH FT218, A ONCE-NIGHTLY SODIUM OXYBATE: POST-HOC RESPONDER ANALYSES FROM THE PHASE 3 REST-ON CLINICAL TRIAL
    Corser, Bruce
    Ajayi, Akinyemi
    Thorpy, Michael
    Seiden, David
    Dubow, Jordan
    Bogan, Richard
    CHEST, 2021, 160 (04) : 2412A - 2414A
  • [25] Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON TrialOnce-Nightly Sodium Oxybate Early EfficacyL. Krahn et al.
    Lois Krahn
    Asim Roy
    John W. Winkelman
    Anne Marie Morse
    Jennifer Gudeman
    CNS Drugs, 2025, 39 (Suppl 1) : 53 - 59
  • [26] Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial
    Roth, Thomas
    Dauvilliers, Yves
    Thorpy, Michael J.
    Kushida, Clete
    Corser, Bruce C.
    Bogan, Richard
    Rosenberg, Russell
    Dubow, Jordan
    Seiden, David
    CNS DRUGS, 2022, 36 (04) : 377 - 387
  • [27] Pharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults
    Seiden, David
    Tyler, Charles
    Dubow, Jordan
    CLINICAL THERAPEUTICS, 2021, 43 (04) : 672 - +
  • [28] Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial
    Thomas Roth
    Yves Dauvilliers
    Michael J. Thorpy
    Clete Kushida
    Bruce C. Corser
    Richard Bogan
    Russell Rosenberg
    Jordan Dubow
    David Seiden
    CNS Drugs, 2022, 36 : 377 - 387
  • [29] IMPROVEMENT IN SLEEP LATENCY WITH FT218 (ONCE-NIGHTLY SODIUM OXYBATE): ANALYSIS FROM THE PHASE 3 REST-ON CLINICAL TRIAL
    Thorpy, Michael
    Shapiro, Colin
    Kushida, Clete
    Ohayon, Maurice
    Dubow, Jordan
    Gudeman, Jennifer
    SLEEP, 2023, 46
  • [30] Weight Loss With Once-nightly Sodium Oxybate for the Treatment of Narcolepsy: Analysis From the Phase III Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium oxybate (REST-ON) Trial
    Roth, Thomas
    Morse, Anne Marie
    Bogan, Richard
    Roy, Asim
    Gudeman, Jennifer
    Dauvilliers, Yves
    CLINICAL THERAPEUTICS, 2024, 46 (10) : 791 - 798
12345